Product Description
CytoSorb is a CE marked extracorporeal cytokine adsorber, designed to broadly reduce inflammatory mediators in the blood that could otherwise lead to uncontrolled systemic inflammation, organ failure, and death in many life-threatening illnesses. (Sourced from: https://cytosorb-therapy.com/en-us/)
Mechanisms of Action: CAR-T
Novel Mechanism: No
Modality: CAR-T
Route of Administration: Intravenous
FDA Designation: Breakthrough Therapy - *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: CytoSorbents
Company Location: MONMOUTH JUNCTION NJ 08852
Company CEO: Phillip Chan
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Pancreatitis, Acute
Phase 3: Shock, Septic|Sepsis|Atherosclerosis|Tumor Lysis Syndrome|Inflammation|Endotoxemia|Brain Ischemia|Reperfusion Injury|Neuromyelitis Optica|Respiratory Paralysis|Liver Failure, Acute|Respiratory Insufficiency|Multiple Sclerosis|Acute Coronary Syndrome|Coronary Occlusion|Acute Kidney Injury|Kidney Diseases|Scleroderma, General|Heart Failure, Acute
Phase 2: Myocardial Ischemia|Rhabdomyolysis|Coronary Artery Disease|Heart Valve Diseases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| COSMOS | N/A |
Recruiting |
Lung Transplant|Hepatic Insufficiency|Endocarditis|Acute Respiratory Distress Syndrome|Shock, Septic|Acute Lung Injury|Shock, Cardiogenic|Drug Overdose|Pancreatitis, Acute|Vasoplegia|Rhabdomyolysis|Respiratory Distress Syndrome, Newborn|Liver Transplant|Respiratory Insufficiency|Lymphohistiocytosis, Hemophagocytic|Acute-On-Chronic Liver Failure|Liver Failure, Acute|Burns Unspecified|Pancreatitis, Chronic|End Stage Liver Disease|Communicable Diseases|Cytokine Release Syndrome |
2032-06-01 |
|
| GLUSorb | N/A |
Recruiting |
Lung Transplant |
2027-12-31 |
|
| CytoHEART | N/A |
Not yet recruiting |
Vasoplegia|Heart Transplant |
2027-04-01 |
|
| DECRISS | P3 |
Suspended |
Shock, Septic |
2026-10-31 |